CrushSCI.com
189.3平均天数
154中位天数
41最短天数
491最长天数
1612025发文量

Paper Review Records

全部论文审稿周期

23 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

145 天

Simvastatin Alleviation of Trimethyltin‐Induced Hippocampal and Behavioral Impairments via Improvement of Antioxidants, Mitochondrial Health, and Energy Homeostasis

作者
Adel Salari; Mahdieh Taheri; Mohsen Khalili; Mehrdad Roghani展开收起
作者单位
1. Department of Animal Biology, Faculty of Biological Sciences Kharazmi University Tehran Iran; 2. Neurophysiology Research Center Shahed University Tehran Iran展开收起
PDF源文件 DOI 网页
310 天

Baricitinib Ameliorates Cutaneous Leukocytoclastic Angiitis in Rats

作者
Yui Arata; Naho Ogawa; Suishin Arai; Takumi Abe; Ayana Sasaki; Mizuki Fukuyama; Hiyori Miyatake; Koki Takai; China Washio; Hodaka Ogawa; Ikuma Hori; Yuka Nishibata; Sakiko Masuda; Utano Tomaru; Tamihiro Kawakami; Akihiro Ishizu展开收起
作者单位
1. Department of Medical Laboratory Science, Faculty of Health Sciences Hokkaido University Sapporo Japan; 2. Department of Surgical Pathology Hokkaido University Hospital Sapporo Japan; 3. Kawakami Dermatology Clinic Matsudo Japan展开收起
PDF源文件 DOI 网页
138 天

Industry Perspective on Current Guidelines, Challenges, and Future Directions for ADME Characterization of Payloads for Antibody‐Drug Conjugates

作者
Vijay More; Kiran Deshpande; Chaitali Passey; Gaurav Bajaj; Jeff Barrett; Manish Gupta展开收起
作者单位
1. Translational and Quantitative Sciences Genmab Inc. Plainsboro New Jersey USA展开收起
PDF源文件 DOI 网页
154 天

Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA ‐76 as a Novel Analgesic in Male Rats and Mice

作者
Kristen L. Woodhouse; Maowei Wang; Sai Ganesh Balaji Venkata Anupindi; Olatunbosun Adeoke; Dehui Zhang; Yanan Zhang; Jun‐Xu Li展开收起
作者单位
1. Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences University at Buffalo Buffalo New York USA; 2. Research Triangle Institute Research Triangle Park North Carolina USA展开收起
PDF源文件 DOI 网页
118 天

Drug Utilization Patterns and WHO Prescribing Indicators Among Hypertensive Outpatients at Karnali Academy of Health Sciences, Nepal: A Cross‐Sectional Study

作者
Bijay Aryal; Birendra Kumar Yadav; Biswash Sapkota; Surakshya Adhikari展开收起
作者单位
1. Department of Clinical Pharmacology School of Health Sciences, Martyr Dasharath Chand University of Health Science Geta, Kailali Nepal; 2. School of Pharmacy Karnali Academy of Health Sciences Jumla Nepal; 3. Department of Pharmacy Madan Bhandari Academy of Health Sciences Hetauda Nepal; 4. Department of Biochemistry Pokhara Academy of Health Sciences Pokhara Nepal展开收起
PDF源文件 DOI 网页
79 天

Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment

作者
Valeria Torralba‐Agu; Natalia Fernández; Carina Shayo; Carlos Davio; C. Daniel Zappia; Federico Monczor展开收起
作者单位
1. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA) Universidad de Buenos Aires Buenos Aires Argentina; 2. Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina; 3. Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental CONICET Buenos Aires Argentina展开收起
PDF源文件 DOI 网页

FAQ

Pharmacology Research & Perspectives审稿要多久?

截至2026-11-17,CrushSCI 收录了 Pharmacology Research & Perspectives 的 23 篇完整审稿记录。最快一篇从收稿到录用用了 41 天(Special Issue on the Promise of Psychedelic Pharmacology in Neuropsychiatric Drug Development,2026-06-11 收稿,2026-07-22 录用),最慢一篇用了 491 天;平均 189.3 天,中位数 154 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。